Segment and Enterprise Wide Disclosures

6 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Segment and Enterprise Wide Disclosures

Note 12. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. International sales (sales outside the U.S., primarily in Europe and Japan) accounted for 13% or total revenue for each of the three and six months ended September 30, 2018, respectively, and 11% and 10% of total revenue for the three and six months ended September 30, 2017, respectively. The Company’s long-lived assets are located in the U.S. except for $39.4 million and $35.5 million at September 30, 2018 and March 31, 2018, respectively, which are located primarily in Germany.